S1B 307
Alternative Names: S1B-307Latest Information Update: 31 Mar 2025
At a glance
- Originator S1 Biopharma
- Class Peptides
- Mechanism of Action Central nervous system modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Anorgasmia; Female sexual dysfunction
Most Recent Events
- 19 Mar 2025 Preclinical trials in Anorgasmia in USA (unspecified route), before March 2025 (S1 Biopharma pipeline, March 2025)
- 19 Mar 2025 Preclinical trials in Female sexual dysfunction in USA (unspecified route), before March 2025 (S1 Biopharma pipeline, March 2025)
- 19 Mar 2025 S1 Biopharma plans a phase I trial for Anorgasmia (S1 Biopharma pipeline, March 2025)